Live
FierceBiotechBrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early dataFierceBiotechNovo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China10x Genomics BlogBioptimus launches spatial biology atlas with 10x Genomics - Investing.comThermo FisherThermo Fisher Scientific Inc. $TMO Stake Decreased by Professional Advisory Services Inc. - MarketBeat10x Genomics BlogBioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs - The Manila TimesAgilentPensionfund Sabic Buys New Position in Agilent Technologies, Inc. $A - MarketBeatEndpoints NewsMaze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex10x Genomics BlogA new atlas aims to map 100,000 patient samples across 3 continents - Stock TitanEndpoints NewsMerck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' ScemblixThermo FisherU.S. Compound Management Market Is Going to Boom | Thermo Fisher - openPR.comThermo FisherThermo Fisher Scientific: Early Clario Close Enhances 2026 Growth Outlook and AI-Driven Competitive Position, Supporting Buy Rating - TipRanksEndpoints NewsGilgamesh's psychedelics pipeline gets $60M backing after AbbVie deal
Endpoints News Jan 6, 2026

Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

Original
Body unavailable. Use the original source.

Directory

59 All